Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients
Author(s) -
Nadia Harbeck,
Inko Nimmrich,
Arndt Hartmann,
Jeffrey S. Ross,
Tanja Čufer,
Robert Grützmann,
Glen Kristiansen,
Angelo Paradiso,
Oliver Hartmann,
Astrid Margossian,
John W.M. Martens,
Ina Schwope,
Antje Lukas,
Volkmar Müller,
Karin MildeLangosch,
Jörg Nährig,
John A. Foekens,
Sabine Maier,
Manfred Schmitt,
Ralf Lesche
Publication year - 2008
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2007.14.1697
Subject(s) - breast cancer , methylation , dna methylation , medicine , oncology , tamoxifen , cancer , hazard ratio , cancer research , biology , gene , gene expression , genetics , confidence interval
We recently reported DNA methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene to be strongly correlated with increased risk of recurrence in node-negative, hormone receptor-positive, tamoxifen-treated breast cancer patients using fresh frozen specimens. Aims of the present study were to establish determination of PITX2 methylation for routine analysis in formalin-fixed paraffin-embedded (FFPE) breast cancer tissue and to test PITX2 DNA methylation as a biomarker for outcome prediction in an independent patient cohort.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom